“A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s631, https://doi.org/10.25251/h9van576.